---
document_datetime: 2024-08-09 11:54:46
document_pages: 35
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/covid-19-vaccine-janssen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: covid-19-vaccine-janssen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 19.4846933
conversion_datetime: 2025-12-28 09:33:32.863018
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0076              | Update of section 4.5 of the SmPC in order to update information regarding the co-administration of JCOVDEN with influenza vaccine based on the final report from study VAC31518COV3005 listed as a category 3 study in the RMP; this is a randomized, double-blind, Phase 3 study to evaluate safety, | 11/07/2024                                  |                                             | SmPC and PL                      | SmPC new text The MAH has submitted the final Clinical Study Report (CSR) for the study COV3005. Study COV3005 is a randomized, double-blind, Phase 3 study to evaluate safety, reactogenicity, and immunogenicity of co- administration of Ad26.COV2.S and influenza vaccines in |

JCOVDEN Procedural steps taken and scientific information after the authorisation Application number Scope Commission Decision Issued 2  / amended Product Information affected 3 Summary II/0076 Update of section 4.5 of the SmPC in order to update information regarding the co-administration of JCOVDEN with influenza vaccine based on the final report from study VAC31518COV3005 listed as a category 3 study in the RMP; this is a randomized, double-blind, Phase 3 study to evaluate safety, SmPC and PL SmPC new text The MAH has submitted the final Clinical Study Report (CSR) for the study COV3005.  Study COV3005 is a randomized, double-blind, Phase 3 study to evaluate safety, reactogenicity, and immunogenicity of coadministration of Ad26.COV2.S and influenza vaccines in Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |               | For         | more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0075/G | This was an application for a group of variations. A grouped application consisting of five Type II variations, as follows: C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3001 listed as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to section 6.1 of the SmPC and to the Package Leaflet. C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3009 listed as a category 3 study in the RMP. This is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, reactogenicity, and immunogenicity of 2 doses of Ad26.COV2.S for the prevention of SARS- CoV-2-mediated COVID-19 in adults aged 18 years and older. C.I.13: Submission of the final report from Medicinal product | 21/03/2024 no | SmPC and PL | SmPC new text The MAH has submitted the final study results of studies COV3001, COV3009 and COV4002. For both studies COV3001 and COV3009, efficacy against confirmed moderate to severe/critical COVID-19 cases and against confirmed severe/critical COVID-19 cases, with onset at least 14 days and/or 28 days after single or 2- dose vaccination by virus variant, for which there are sufficient cases available for meaningful interpretations are included in the SmPC. Final efficacy analysis by variant has been updated in section 5.1 of the SmPC based on complete genome sequencing data. Final safety results from the above studies are aligned with safety data from the primary analysis. No new safety concern is identified. Final results of the COV4002 collectively indicate that, in the US population, as compared to no vaccination and for the period covered by this study, administration of a single dose of JCOVDEN results in a lower risk for developing COVID-19, for being hospitalized for COVID-19, and for all- cause mortality temporally associated with COVID-19 for at least 12 months. Vaccine effectiveness increased as the outcome severity increased, and relatively lower vaccine effectiveness were estimated in groups at higher risk of COVID-19. For more information, please refer to the Summary of Product Characteristics. longer authorised |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0074/G           | This was an application for a group of variations. Grouped application comprising two type II variations (C.I.13) as follows: - Submission of the final report from study TOX15258 - Ad26.COV2.S (Prophylactic COVID-19 Vaccine): A Transcriptomics Exploratory Study in Cambodian Cynomolgus Monkey. - Submission of the report from study TV-TEC- 236300 - Biophysical studies on interactions between human platelet 4 and Ad26.COV2.S. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority product | 12/10/2023 | n/a no     | longer      | authorised                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10916 /202302 | Periodic Safety Update EU Single assessment - COVID-19 vaccine (Ad26.COV2-S [recombinant]) (JCOVDEN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/09/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                     |
| II/0072/G           | This was an application for a group of variations. Update of section 4.4 of the SmPC in order to add a new warning on myocarditis and pericarditis and update of section 4.8 of the SmPC to add myocarditis and pericarditis to the list of adverse drug reactions (ADRs) with frequency not known based on post- Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/05/2023 | 29/06/2023 | SmPC and PL | The overall current safety profile of the JCOVDEN is established based on available data from all sources, including spontaneous reports from the MAH's global safety database, available clinical study data and Real World Evidence (RWE) analyses. Myocarditis and pericarditis are adverse events of special interest (AESI) which have been reviewed in previous |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 2a study to evaluate a range of dose levels and vaccination intervals of Ad26.COV2.S in healthy adults aged 18 to 55 years, and adults aged 65 years and older. The RMP version 7.1 is submitted and updated accordingly. In addition, the MAH updated the milestones of several studies. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | longer authorised                                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| PSUSA/10916 /202208 | Periodic Safety Update EU Single assessment - COVID-19 vaccine (Ad26.COV2-S [recombinant]) (JCOVDEN) 14/04/2023 no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | PRAC Recommendation - maintenance                                             |
| II/0065             | Submission of an updated RMP version 5.3 in order to update the clinical exposure and risk sections. In addition, the study VAC31518COV3018 is removed from the RMP. This is an interventional clinical trial to evaluate the immunogenicity and safety of JCOVDEN in immunocompromised patients. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH 09/02/2023 Medicinal product                                                                                                   | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|           | where significant assessment is required                                                                                                                                                                                                                    |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0063    | Renewal of the marketing authorisation.                                                                                                                                                                                                                     | 15/12/2022 | 09/01/2023 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have either been fulfilled or reclassified as Category 3 study in the RMP, there are no remaining grounds for the marketing authorisations to remain conditional and therefore recommends the granting of the MA no longer subject to Specific Obligations for JCOVDEN. Please refer to Scientific Discussion 'JCOVDEN/H/C/005737/R/0063' longer authorised |
| IB/0070/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure product | 22/12/2022 | n/a no     |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0067   | B.I.z - Quality change - Active substance - Other variation Medicinal                                                                                                                                                                                       | 08/12/2022 | 05/01/2023 | Annex II | Annex II.E has been updated to remove the specific obligation related to the request for additional active substance comparability and validation data.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0064   | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                  | 08/12/2022 | 05/01/2023 | Annex II | Annex II.E has been updated to remove the specific obligation related to the request for additional finished product comparability and validation data.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0053/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/11/2022   | 11/11/2022   | SmPC and PL   | SmPC new text                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | Update of section 4.2 of the SmpC to introduce an heterologous booster dose of JCOVDEN following priming with another adenoviral vector-based vaccine based on literature evidence from COV- BOOST study. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as heterologous booster dose based on data from studies COV-BOOST study. Update of sections 4.8 of the SmPC to include safety and immunogenicity data of JCOVDEN as homologous and heterologous booster dose based on data from COV2008 study, a randomised, double- blind Phase 2 Study Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as heterologous booster dose based on data from DMID 21-0012 study. In addition, updated vaccine efficacy by variant has been updated based on updated genomic sequencing data from study COV3009 and some minor corrections have been implemented in in section 5.1 of the SmPC. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product |              | no           |               | This variation has been submitted to introduce an heterologous booster with Ad26.COV2.S following primary vaccination with another adenoviral vector-based vaccine and to provide updated follow-up data from studies which were included in variation EMEA/H/C/005737/II/0033. As a consequence, section 4.2, 4.8 and 5.1 of the SmpC have been updated. The PL has been updated accordingly. Data of the COV-BOOST study were submitted to support the heterologous booster with Ad26.COV2.S following another adenoviral vector-based primary vaccination. This study evaluates safety and immunogenicity of different COVID-19 vaccines given as third dose (booster) after primary vaccination with adenoviral-vector based or mRNA COVID-19 vaccines. The data showed that a booster dose of Ad26.COV2.S induces anamnestic humoral responses in individuals who completed their primary vaccination schedule with 2 doses of ChAdOx1 approximately 77 days before the booster vaccination. Data from study DMID 21-0012, and independent Phase 1/2 open-label clinical trial study (NCT04889209) that evaluated immunogenicity and safety of a booster injection of Ad26.COV2.S or an mRNA vaccine 12 weeks after primary vaccination with a COVID-19 vaccine were further complemented with long-term nAb data for the reference strain D614G, nAb data against the Delta and Beta variants, as well as CMI data. Ad26.COV2.S induced a booster response 15 days post boost against the reference strain as well as the Beta and the Delta variants in individuals primed with a mRNA vaccine who received the booster at least 12 weeks after primary vaccination. Immunogenicity data against the Omicron BA.1 variant longer authorised |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |                                  |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0069/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                        | 01/11/2022 | n/a                              | authorised                                                                                                                                 |
| PSUSA/10916 /202202 | Periodic Safety Update EU Single assessment - COVID-19 vaccine (Ad26.COV2-S [recombinant]) (JCOVDEN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/10/2022 | 31/10/2022 SmPC and PL no longer | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10916/202202. |
| II/0047/G           | This was an application for a group of variations. Submission of the final reports from the non-clinical studies TV-TEC-207316, TV-TEC-207437, TOX15155, TV-TEC-215524 and TOX15252, listed as category 3 in the RMP. These are non-clinical studies conducted to further characterise the potential mechanisms underlying the important identified risks of thrombosis with thrombocytopenia syndrome (TTS) and thrombocytopenia, including immune thrombocytopenia (ITP). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal product | 13/10/2022 | n/a                              |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | longer authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0060 | Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) based on pooled analyses of clinical safety data from the following Phase III interventional studies: VAC31518COV3001 and VAC31518COV3009; and from the Phase I/II interventional studies: VAC31518COV1001, VAC31518COV1002, VAC31518COV1003 and VAC31518COV2001. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data 15/09/2022 Medicinal product                               | SmPC new text The safety profile of the primary vaccination with Ad26.COV2.S in adults aged 18 years of age and older described in the current SmPC is based on the safety results from the primary analysis from the double-blind phase of the Phase 3 Study VAC31518COV3001 (data cut- off: 22 January 2021) and on post-marketing data which became available following the initial authorization of the vaccine. With the availability of data from final analyses of the double-blind phases of Study VAC31518COV3001 and the second large double-blind Phase 3 Study VAC31518COV3009, available safety data on vaccination with Ad26.COV2.S in a randomized, placebo-controlled clinical setting data increased substantially compared with the amount of safety data available at the time of the initial filing. The Marketing Authorisation Holder (MAH) has performed a primary pooled analysis of clinical safety data from the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                |            | no longer   | double-blind phases of Phase 3 studies (VAC31518COV3001 and VAC31518COV3009), and from Phase 1 and Phase 2 clinical studies (VAC31518COV1001, VAC31518COV1002, VAC31518COV2001) with Ad26.COV2.S 5Ã—1010 vp (18 November 2021) to assess the reactogenicity profile and the frequency of adverse events after primary vaccination with Ad26.COV2.S in adults aged 18 years and older. Current identified adverse drug reactions (ADRs) in the approved SmPC were retained as ADRs in the proposed SmPC, but their frequency categories were revised. No new ADRs following vaccination with Ad26.COV2.S were identified based on the results of the primary pooled analysis compared to the current approved safety profile. The package leaflet is updated accordingly. The benefit-risk balance of JCOVDEN remains positive. For more information, please refer to the Summary of Product Characteristics. authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0062   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product product                                                            | 08/09/2022 | n/a         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0058/G | This was an application for a group of variations. B.II.d.z - Change in control of the Finished Product - Other variation B.II.b.z - Change in manufacture of the Finished Product - Other variation Medicinal | 01/09/2022 | n/a         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0057   | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                     | 01/09/2022 | n/a         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0061   | B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/08/2022   | n/a        |                                                                                                                                                                                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0059   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/07/2022   | 31/10/2022 | Annex II To extend the due date of SOB \"Ãn order to confirm the consistency of the finished product manufacturing process, the MAH should provide additional comparability and validation data.\" from 31st of October 2022to 30th of authorised |
| II/0048/G | This was an application for a group of variations. Submission of the final reports from four exploratory studies conducted to further characterise the potential mechanisms underlying the important identified risk of thrombosis with thrombocytopenia syndrome (TTS). These studies evaluated the levels of anti-PF4 antibodies using clinical samples, both from Ad26.COV2.S and other non-COVID-19 Ad26- based vaccine clinical studies. Interim results from an additional exploratory study are provided and the submission milestone for the final results has been updated. The RMP version 4.2 has been updated accordingly. In addition, the MAH removed the important identified risk of anaphylaxis from the list of safety concerns (PSUSA/00010916/202108), updated the routine pharmacovigilance activities section and took the opportunity to implement other administrative updates in the RMP in alignment with procedure EMEA/H/C/005737/II/033. Medicinal product | 07/07/2022   | n/a no     | September 2022. longer                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | longer authorised                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050   | B.II.b.z - Change in manufacture of the Finished Product - Other variation 10/06/2022 n/a no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| IB/0056   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product 09/06/2022 n/a product                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                 |
| IB/0055/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product 31/05/2022 31/10/2022 Medicinal                                                                                                                                               | This variation resulted in an update of annex II to include a new specific obligation to confirm the consistency of the active substance manufacturing process. |

<div style=\"page-break-after: always\"></div>

| IB/0052/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 24/05/2022   | 31/10/2022    | Annex II                                 | This variation resulted in an update of annex II to amend due date of the specific obligation to confirm the                                                                                                |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0051     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 18/05/2022   | 25/05/2022    | consistency SmPC, Annex II and PL longer | of the finished product manufacturing process. To update section 4.8 of the SmPC and section 4 of the PL to add Cutaneous small vessel vasculitis as adverse reaction with frequency 'Not known' authorised |
| IB/0046     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/05/2022   | n/a           |                                          |                                                                                                                                                                                                             |
| IAIN/0049   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/04/2022   | 17/05/2022 no | SmPC, Labelling and PL                   | To change the (invented) name of the medicinal product from COVID-19 Vaccine Janssen to JCOVDEN.                                                                                                            |
| II/0041/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening Medicinal product | 31/03/2022   | n/a           |                                          |                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.e.4.a - Changes to an approved change management protocol - Major changes                                                                                                                                                                                                                                                                                                                                                                             | authorised                                      |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| II/0040             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/03/2022 n/a                                  |
| PSUSA/10916 /202108 | Periodic Safety Update EU Single assessment - COVID-19 vaccine (Ad26.COV2-S [recombinant]) (JCOVDEN) 10/03/2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | n/a PRAC Recommendation - maintenance no longer |
| IB/0045/G           | This was an application for a group of variations. B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to 08/03/2022 Medicinal product | n/a                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | OCABR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |               |                        |                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|---------------------------------------------------------------------------------------------------|
| IB/0044/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                               | 01/03/2022 | n/a           | longer                 | authorised                                                                                        |
| IB/0043/G | This was an application for a group of variations. B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Medicinal product | 24/02/2022 | 02/03/2022 no | SmPC, Labelling and PL | Update of the PI to extend the shelf life from 4.5 months to 11 months when stored at 2Â°C to 8Â°C. |
| IB/0042   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/02/2022 | n/a           |                        |                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0037   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/02/2022   | 02/03/2022    | Annex II               | Annex II has been updated to delete the following obligation: 'In order to confirm the consistency of the active substance manufacturing process, the MAH should provide additional comparability and validation data.'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035   | Update of section 4.4 and 4.8 of the SmPC in order to add transverse myelitis to the list of warnings and precautions and to the list of adverse drug reactions (ADRs) with frequency 'not known' based on the PRAC request from the post-authorisation measures MEA 14.5 and MEA 14.6 (6th and 7th Monthly Summary Safety Report covering the months of August 2021 and September 2021, respectively). The Package Leaflet is updated accordingly. Update of section 4.4 of the SmPC in order to amend the wording on Thrombosis and thrombocytopenia syndrome (TTS) following the PRAC request from the post-authorisation measure MEA 14.5. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement an editorial Quality review document (QRD) comment in the labelling following procedure EMEA/H/C/005737/II/014. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 13/01/2022   | 14/01/2022 no | SmPC, Labelling and PL | As an outcome of the post-authorisation measure MEA 14.5 and 14.6 (6th and 7th Monthly Summary Safety Report covering the months of August and September 2021), the MAH was requested to update of sections 4.4 and 4.8 of the SmPC in order to add transverse myelitis to the list of warnings and precautions and to the list of adverse drug reactions (ADR) with frequency not known. Based on a cumulative review of post-marketing data and literature on transverse myelitis up to 31st September 2021, it was concluded that there was a reasonable possibility to consider transverse myelitis as causally related to the COVID-19 vaccine Janssen and therefore, it was added to section 4.8 of the SmPC. The frequency of this event was calculated as 'not known'. In addition, considering transverse myelitis is a serious condition, albeit occurring very rarely, it is considered warranted to add information in section 4.4 to raise awareness among prescribers as well as vaccinees in case of experiences signs and symptoms which may suggest transverse myelitis. In addition, section 4.4 of the SmPC has been updated in order to amend the wording on Thrombosis and thrombocytopenia syndrome (TTS) and reflect the observed balanced gender in the TTS cases reported through the post-marketing data. The package leaflet is updated accordingly. longer authorised |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |        | For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|---------------------------------------------------------------------------------|
| II/0029   | Submission of an updated RMP version 3.1 in order to upgrade the important potential risk of venous thromboembolism (VTE) to an important identified risk as an outcome of the procedure MEA-32, addition of the clinical trial VAC31518COV3003 and update of study VAC18193RSV2008 as additional pharmacovigilance activities to further characterize the important identified risks of Thrombosis with thrombocytopenia syndrome (TTS), thrombocytopenia (including immune thrombocytopenia) and VTE as an outcome of MEA 14.4. The MAH took the opportunity to include other minor updates in the RMP. In addition, the MAH consolidated in RMP version 3.1 the updates made in the RMP as part of the approved procedure EMEA/H/C/005737/II/0018 and procedure EMEA/H/C/005737/II/0029. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal product | 13/01/2022 | n/a no | longer authorised                                                               |
| IB/0039/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/01/2022 | n/a    |                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                            |            |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0023  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/12/2021 | 03/01/2022 no | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for COVID-19 Vaccine Janssen, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. longer authorised                                                                                                                                                                                              |
| II/0033 | Update of sections 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC in order to introduce an homologous booster dose (second dose) of COVID-19 vaccine Janssen based on interim efficacy, immunogenicity and safety results from different clinical studies including the two randomised, double blind, placebo-controlled Phase 3 studies COV3001 and COV3009. A contraindication in individuals with a history thrombosis with thrombocytopenia syndrome following vaccination with any COVID-19 vaccine is also included. In addition, an update to introduce an heterologous booster dose of COVID-19 vaccine Janssen following completion of a primary vaccination with an approved mRNA COVID-19 Medicinal product | 14/12/2021 | 16/12/2021    | A booster dose (second dose) of 0.5 mL of COVID-19 Vaccine Janssen may be administered intramuscularly at least 2 months after the primary vaccination in individuals 18 years of age and older. A booster dose of the COVID-19 Vaccine Janssen (0.5 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorised for a booster dose of the vaccine used for primary vaccination. Individuals who have experienced thrombosis with thrombocytopenia syndrome (TTS) following vaccination with any COVID-19 vaccine should not receive COVID-19 |

<div style=\"page-break-after: always\"></div>

The risk of very rare events (such as coagulation disorders including thrombosis with thrombocytopenia syndrome, CLS and GBS) after a booster dose of COVID-19 Vaccine Janssen has not yet been characterised. Efficacy of two-doses of COVID-19 Vaccine Janssen administered 2 months apart A final analysis (cut-off date 25 June 2021) of a multicentre, randomised, double-blind, placebo-controlled Phase 3 study (COV3009) was conducted to assess the efficacy, safety, and immunogenicity of 2 doses of COVID19 Vaccine Janssen administered with a 56-day interval. In total, 14492 individuals were included in the perprotocol efficacy population (7484 individuals received COVID-19 Vaccine Janssen and 7008 individuals received placebo).

Vaccine efficacy against symptomatic infections at least 14 days after second vaccination was 75.2% (95% CI: 54.6; 87.3).

Immunogenicity of a booster dose (second dose) following primary vaccination with COVID-19 Vaccine Janssen In a Phase 2 Study (COV2001), individuals 18 through 55 years of age and 65 years and older received a booster dose of the COVID-19 Vaccine Janssen approximately 2 months after the primary vaccination. Immunogenicity data are available from 39 individuals, of whom 15 were 65 years of age and older. Neutralising antibody and binding antibody increases against the reference SARS-CoV-2 strain were also observed in studies COV1001, COV1002 and COV2001 in a limited number of study participants after a boost given at 2, 3 and 6 months, when compared to preboost values. Overall, the increases of GMTs pre-boost to vaccine is introduced based on immunogenicity and safety interim results from the phase 1/2 study DMID 21-0012. In addition, the MAH took the opportunity to update the efficacy data for the primary vaccination schedule based on final analysis from study COV3001. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Vaccine Janssen Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

1-month post-boost ranged from 1.5 to 4.4 fold for neutralising antibodies, and from 2.5 to 5.8 fold for binding antibodies. A 2-fold decrease in antibody levels was observed 4 months following 2-month booster dose, compared to 1 month following 2-month booster dose. Antibody levels were still higher than antibody levels following a single-dose at a similar timepoint. These data support the administration of a booster dose when administered at an interval of 2 months or longer after primary vaccination.

Immunogenicity of a booster dose following primary vaccination with an approved mRNA COVID-19 vaccine An independent Phase 1/2 open-label clinical trial (NCT04889209) conducted in the United States evaluated a heterologous booster dose of the COVID-19 Vaccine Janssen. Due to the limited sample size, differences observed are only descriptive. In this study, adults who had completed primary vaccination with a Spikevax 2-dose series (N=151), a COVID-19 Vaccine Janssen single-dose (N=156), or a Comirnaty 2-dose series (N=151) at least 12 weeks prior to enrollment and who reported no history of SARS-CoV-2 infection were randomised 1:1:1 to receive a booster dose of one of three vaccines: Spikevax, COVID-19 Vaccine Janssen or Comirnaty. Neutralising antibody titres were assessed on Day 1 prior to administration of the booster dose and on Day 15 and Day 29 after the booster dose. A booster response to the COVID-19 Vaccine Janssen was demonstrated regardless of primary vaccination. The antibody level 14 days after a heterologous boost by COVID-19 Vaccine Janssen is lower than after a homologous boost by a licensed mRNA vaccine while after 1 month, neutralising antibody titers are roughly similar

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                |            |            |          | between both regimens. Data indicate the homologous regimen with COVID-19 Vaccine Janssen induces lower antibody responses compared to heterologous boosting with a licensed mRNA vaccine. The clinical relevance of this is unknown. Only short-term immunogenicity data are available, long-term protection and immunological memory are currently unknown. For more information, please refer to the Summary of Product Characteristics. authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.z - Change in manufacture of the Finished Product - Other variation | 16/12/2021 | n/a no     | longer   |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0036   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product product                                                                                                                                                                           | 13/12/2021 | 16/12/2021 | Annex II | Update on the dates for a Specific Obligation listed in Annex II.                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0032   | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB Medicinal                                                                                                                                                                              | 10/12/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0038   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                     | 03/12/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0018   | Submission of an updated RMP version 2.5 in order                                                                                                                                                                                                                                                                              | 02/12/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0030   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                 | 23/11/2021   | n/a           |             | authorised                                                                                                                                                                                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017   | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                           | 21/10/2021   | n/a           |             |                                                                                                                                                                                                                     |
| IB/0028/G | This was an application for a group of variations. B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                          | 11/10/2021   | n/a           | longer      |                                                                                                                                                                                                                     |
| IB/0027   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                       | 08/10/2021   | 11/10/2021 no | SmPC and PL | To include Venous Thromboembolism (VTE) as Adverse Drug Reaction.                                                                                                                                                   |
| IB/0025/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product Medicinal product | 01/10/2021   | 11/10/2021    | Annex II    | This variation resulted in an update of annex II to include an update of the specific obligation to confirm the consistency of the finished product manufacturing process, with the addition of interim reports     |
| II/0020   | Update of sections 4.4 and 4.8 of the SmPC to add a new warning on immune thrombocytopenia (ITP), and to add dizziness and ITP to the list of adverse drug reactions with frequencies uncommon and not                                                                                                               | 30/09/2021   | 01/10/2021    | SmPC and PL | As an outcome of the post-authorisation measure MEA 14.3 (4th Monthly Summary Safety Report covering June 2021), the MAH was requested to update of sections 4.4 and 4.8 of the SmPC to add a new warning on immune |

<div style=\"page-break-after: always\"></div>

known, respectively; based on the PRAC request from the post-authorisation measure MEA/014.3 (4th Monthly Summary Safety Report covering the month of June 2021). The package leaflet is updated accordingly. A DHPC and communication plan was adopted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data thrombocytopenia (ITP), and to add dizziness and ITP to the list of adverse drug reactions with frequencies uncommon and not known, respectively. Based on a cumulative review of post-marketing data on anxiety related reactions, including dizziness, it was concluded there was a reasonable possibility to consider dizziness as causally related to the COVID-19 vaccine Janssen, and therefore, it was added to section 4.8 of the SmPC. The frequency of this event was calculated as 'uncommon' based on clinical data from study VAC31518COV3001. ITP was added to section 4.8 following a review of the available post-marketing and clinical trial data. In addition, taking case reviews into account, and particularly due to the severity of some cases reported, as well as limited post-marketing and literature data showing significant decrease in platelet values in patients with a prior medical history of ITP following vaccination with the Janssen COVID-19 vaccine, a warning in section 4.4 of the SmPC is added. A Direct Healthcare Professional Communication (DHPC) is considered necessary in order to communicate on the new recommendations in relation to ITP; namely that Healthcare professionals (HCPs) 1. should assess an individual's relevant medical history prior to administering COVID-19 Vaccine Janssen and discuss the risks and benefits of developing low platelet levels before administering the vaccine, 2.should be alert to signs and symptoms of ITP, such as spontaneous bleeding, bruising or petechiae and 3. are recommended to monitor platelet levels in individuals with a history of ITP following vaccination with COVID-19 Vaccine Janssen. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0024/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                          | 21/09/2021 | 29/09/2021 | SmPC, Labelling and PL | To extend the shelf life of the Covid-19 vaccine Janssen drug product in accordance with the approved stability protocol from the current shelf-life of 3 months to 4.5 months when stored at 2 to 8Â°C. To clarify in Annex 1 - Summary of Product Characteristics, 6.3 Shelf life and 6.4 Special precautions for storage and the corresponding section in the Package leaflet that transportation is also part of the chemical and physical in- use stability of the opened vial (after first puncture). authorised |
| IB/0022/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process product                                                                                                             | 07/09/2021 | n/a no     | longer                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0021/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a Medicinal | 06/09/2021 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0019   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2021   | n/a                              | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/08/2021   | n/a                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0015   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/07/2021   | 03/09/2021 Annex II              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0012   | Update of sections 4.4 and 4.8 of the SmPC in order to add a warning related to the possibility of developing a Guillain-BarrÃ© syndrome (GBS) following the administration of Ad26.COV2.S and to add GBS as an adverse drug reaction (ADR). This is based on the information accumulated on cases of GBS reported to the vaccine adverse event reporting system (VAERS) in recipients of the Janssen COVID- 19 Vaccine and subsequently, on the analysis performed by the company on cases of GBS based on the available cumulative data from launch. In addition, the company took the oportunity to make some editorial changes. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 22/07/2021   | 23/07/2021 SmPC and PL no longer | SmPC new text A warning is added in 4.4 of the SmPC regarding the possibility of presenting a Guillain -BarrÃ© Syndrome (GBS) after the administration of Janssen COVID-19 Vaccine. This adverse event is also added in 4.8 of the SmPC with a frequency of very rare. Healthcare professionals should be alert of GBS signs and symptoms to ensure correct diagnosis, in order to initiate adequate supportive care and treatment and to rule out other causes. |

<div style=\"page-break-after: always\"></div>

| IB/0013   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/07/2021   | 23/07/2021    | Annex II    | To extend the due date of the specific obligation and update Annex II of the product information accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010   | Update of section 4.3, 4.4 and 4.8 of the SmPC in order to add a contraindication related to the administration of Ad26.COV2.S to individuals with a history of Capillary Leak Syndrome (CLS) based on the cases reported following administration of this vaccine in the Global Medical Safety (GMS) up to the data lock point (DLP) of 21 June 2021. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to add some minor editorial changes throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 07/07/2021   | 09/07/2021 no | SmPC and PL | SmPC new text The administration of this vaccine (Ad26.COV2.S) is contraindicated in individuals with a history of Capillary Leak Syndrome (CLS). A joint DHPC is issued to alert health care professionals to the signs and symptoms of thromboembolism and/or thrombocytopenia in follow up to the adopted signal procedure at PRAC for TTS (Thrombosis with Thrombopenia Syndrome).This letter also communicate the new contraindication of this vaccine in individuals who have previously experienced episodes of Capillary Leak Syndrome (CLS). For more information, please refer to the Summary of Product Characteristics. longer authorised                       |
| II/0006/G | This was an application for a group of variations. To update the EU-RMP for COVID-19 Vaccine Janssen to include thrombosis with thrombocytopenia syndrome (TTS) in the list of the safety concerns as an important identified risk following the PRAC recommendation, dated 6 May 2021 in the outcome of the related signal of Embolic and Thrombotic events (procedure number SDA 018.1) with COVID- 19 Vaccine Janssen (Ad26.COV2-S [recombinant]) . In addition, the MAH sought agreement on a DHPC to alert health care professionals to the signs and symptoms of thromboembolism and/or Medicinal product                        | 07/07/2021   | n/a           |             | Thrombosis with thrombocytopenia syndrome (TTS) is included in the list of the safety concerns as an important identified risk in the outcome of the related signal of Embolic and Thrombotic events (procedure number SDA 018.1) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]). In addition, Thrombocytopenia is also agreed to be included as an important potential risk in the summary of safety concerns in the RMP. The RMP will be updated within the next expected variation to update the RMP. Finally, a joint DHPC is issued to alert health care professionals to the signs and symptoms of thromboembolism and/or thrombocytopenia in follow up to |

<div style=\"page-break-after: always\"></div>

|         | thrombocytopenia in follow up to the adopted signal procedure at PRAC for TTS (Thrombosis with Thrombopenia Syndrome). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |                          | longer   | the adopted signal procedure at PRAC for TTS (Thrombosis with Thrombopenia Syndrome). This letter also communicates the new contraindication of this vaccine in individuals who have previously experienced episodes of Capillary Leak Syndrome (CLS). SmPC new text No changes are introduced in the SmPC or in the Product Leaflet. authorised   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011 | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                               | 30/06/2021 09/07/2021 no | Annex II | This variation resulted in an update of annex II to add a specific obligation to confirm the consistency of the active substance manufacturing process by submitting additional comparability and validation data.                                                                                                                                 |
| IA/0009 | A.7 - Administrative change - Deletion of manufacturing sites product                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/06/2021 n/a           |          |                                                                                                                                                                                                                                                                                                                                                    |
| II/0005 | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/06/2021 n/a           |          |                                                                                                                                                                                                                                                                                                                                                    |
| IB/0008 | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product Medicinal                                                                                                                                                                                                                                                                                                                                                                                    | 21/06/2021 09/07/2021    | Annex II | This variation resulted in an update of annex II to amend the specific obligation to confirm the consistency of the finished product manufacturing process, with the addition of interim reports.                                                                                                                                                  |
| IB/0007 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                      | 01/06/2021 n/a           |          |                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0004   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                         | 07/05/2021   | 07/05/2021    | SmPC and PL                      | This variation is to update section 4.4 of the SmPC and sections 2, 4 and 6 of the package leaflet (PL) to implement the updated signal recommendations on embolic and thrombotic events (EPITT no 19689), following receipt of an updated PRAC signal assessment report on additional data and adoption at PRAC plenary on 05th of April 2021. Leg pain, seizures and mental status changes have been added as symptoms for thrombosis with thrombocytopenia syndrome, as well as the need to actively investigate for sign of thrombosis individuals diagnosed with thrombocytopenia within 3 weeks after vaccination with COVID-19 Vaccine Janssen. Similarly, individuals who present with thrombosis within 3 weeks of vaccination should be evaluated for thrombocytopenia. longer authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0003   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation product                                                                                                                                                 | 21/04/2021   | 22/04/2021 no | SmPC and PL                      | This variation is to update sections 4.4 and 4.8 of the SmPC and sections 2, 4 and 6 of the package leaflet (PL) to implement the signal recommendations on embolic and thrombotic events (EPITT no 19689), following receipt of an updated PRAC signal assessment report on additional data and adoption at PRAC plenary on 20th of April 2021. A new warning on thrombocytopenia and coagulation disorder is added and the adverse reaction: thrombosis in combination with thrombocytopenia is introduced with a frequency: very rare (<1/10 000).                                                                                                                                                                                                                                                 |
| IB/0002/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.f.z - Stability of FP - Other variation Medicinal | 15/04/2021   | 22/04/2021    | SmPC, Annex II, Labelling and PL | This variation resulted in an update of sections 6.1, 6.4, 6.5 and 8 of the SmPC, annex II, labelling and Package Leaflet to include: - the addition of a new pack size of 20 vials with a slightly different composition (removal of Trisodium citrate dihydrate)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.a.3.b.6 - Changes in the composition (excipients) of the finished product - Other excipients - Replacement of a single excipient with a comparable excipient with the same functional characteristics and at a similar level B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a   | - a change from 12 to 13 hours to the thawing time - an update of the specific obligation to confirm the consistency of the finished product manufacturing process, with the addition of interim reports longer authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0001/G | biological/immunological medicinal product This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product 06/04/2021 22/04/2021 Medicinal product no                                                                                                                                                                                               | This variation resulted in an update of annex II to amend the specific obligation to confirm the consistency of the finished product manufacturing process, with the addition of interim reports.                            |